Prognosis and Management of Stage D Heart Failure

Introduction to Stage D Heart Failure

The American College of Cardiology and American Heart Association classify dependence on continuous or intermittent intravenous inotropic support as a defining feature of Stage D heart failure, the most advanced stage with the worst prognosis 1, 2, 5

Patients with Stage D heart failure, like the 87-year-old male described, have a poor prognosis with expected survival measured in days to weeks after discontinuing inotropes, due to severe left ventricular dysfunction and inotrope dependence 1, 2
The American College of Cardiology and American Heart Association guidelines indicate that Stage D heart failure patients have the highest mortality risk, with a 5-year survival rate after hospitalization for HFrEF of only 25% 1, 2

Withdrawal of inotropic support will result in rapid hemodynamic deterioration, with cardiac output declining precipitously and end-organ hypoperfusion developing, affecting kidneys, liver, brain, and other vital organs 1, 2, 4
Cardiogenic shock is likely, given the patient's demonstrated dependence on inotropes to maintain systemic perfusion 2, 3

The American College of Cardiology and American Heart Association guidelines acknowledge that inotropes do not improve survival and carry significant risks, including arrhythmias and increased mortality, but may be considered for palliative therapy in select patients with Stage D HF 1, 2, 6
The guidelines indicate a Class IIb recommendation for long-term continuous intravenous inotropic support for palliative therapy in select patients with Stage D HF who are not candidates for mechanical circulatory support or transplantation 1, 2

Mechanical circulatory support is not likely an option for this patient given his age and functional status, as the guidelines indicate that MCS is reasonable for carefully selected patients with Stage D HFrEF, but patient selection requires consideration of age, comorbidities, functional status, and social support 2, 3, 5, 7
Cardiac transplantation is definitively not an option given the patient's age, as transplant evaluation is indicated for carefully selected patients with Stage D HF, but age 87 exceeds all transplant center criteria 3, 7
A palliative care approach is the most appropriate framework for this patient, with goals-of-care discussion, aggressive symptom management, and hospice-level support for patient and family 1, 2, 8

The decision pathway for this patient involves assessing candidacy for advanced therapies, clarifying goals of care, and implementing comprehensive palliative care with aggressive symptom management if discontinuing inotropes 1, 2, 8